ASX 50

We see clear risks going forward and believe it is prudent to price them into valuations.

Iron ore peaked at US$140/t in January but is now closing in on the psychological US$100/t support level. We investigate how low might go.

How could you justify buying a bank that's almost twice as expensive as its peers, with a market cap that's three times its balance sheet.

We take a look at how the members of the Centurion Club (stocks with 1-yr forward P/Es over 100) have performed over the past 12 months.

We still believe QBE Insurance is well-positioned for long-term growth.

The copper price has completely retraced its March-May rally. Major broker Macquarie considers what’s next for Dr Copper.

Australia's biggest healthcare stock disappointed on guidance for FY25, sending its share price south.

Data doesn't always uncover the granular nuances of the economy. That's where company earnings can help.

For background information about this A1-quality company, I previewed REA Group’s (ASX:REA) latest results here, wrote about why I believe REA Group is one of...

A handful of stock ideas that could prove useful should the weather turn nasty.

Ray David from Blackwattle Investment Partners discusses the transformation underway at News Corp led by CEO Robert Thomson.

Markets seesaw in wild week: S&P 500's worst day since 2022, Japan's whiplash rally, and more as investors ride volatility rollercoaster.

Read on to find the ratings, consensus price targets, and FNArena insights on each stock covered.

And four narratives that will be tested this reporting season...

We look at five of the biggest developments across global markets for the week ending 9 August 2024

Despite challenges like inflation and finance costs, Transurban will retain its position in The Montgomery Fund’s portfolio.

Are these ASX companies the investing equivalent to some of the world's great Olympians? I'll take a look.

There are several pieces of credible evidence to support the case for a price bounce, which would be good news for fast-growing Patriot.

Wilsons Advisory’s Melissa Benson and Shane Storey share their insights in the final part of the biotech mini-series.

We delve into the case for prioritising Value for a pathway beyond the current market conditions.

Aka the "lazy" way to build up your share portfolio.

From digging for unloved value to discovering the best founder-led companies, these investors have different views on how to generate alpha.

The most important month of the investing year is here - and the stakes are very high.

ResMed (ASX:RMD) reported its June quarter and full year results after the U.S. market closed on Friday morning. The company met consensus expectations for both...